SEATTLE, May 5, 2015 /PRNewswire/ -- CMC Biologics, Inc., a global CMO dedicated to process development and production of biopharmaceuticals for clinical and commercial use, today announced that it will supply bulk drug substance for Emergent BioSolutions’ recently FDA-approved product, IXINITY® [coagulation factor IX (recombinant)]. IXINITY is a lyophilized powder for solution for intravenous injection. It is a coagulation factor IX (recombinant) indicated in adults and children 12 years of age with hemophilia B for control and prevention of bleeding episodes, and for perioperative management. Hemophilia B is a bleeding disorder caused by a mutation on the factor IX gene resulting in a deficiency of clotting factor IX in the blood, which controls bleeding.
“Working in partnership with Emergent to achieve this important commercial milestone has been a major focus for the entire CMC Biologics team,” said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics. “We manufactured the coagulation factor IX (recombinant) drug substance for all of the clinical trials. We are proud to have played such an important role in the development of IXINITY.”
CMC Biologics has an agreement with Emergent for the exclusive manufacture of the coagulation factor IX (recombinant) drug substance. CMC Biologics’ facility in Bothell, WA was inspected by the FDA as part of the approval for the commercial manufacture of IXINITY.
“We are extremely pleased to help Emergent provide this critical treatment option to patients for management of hemophilia B,” said Claes Glassell, Chief Executive Officer of CMC Biologics. “We are committed to providing innovative development and manufacturing solutions for all of our clients to bring their products to the market.”
About CMC Biologics
CMC Biologics is leading the industry among CDMOs in reliability, technical excellence, and quality Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical, and commercial production. The Company’s wide range of integrated services includes cell line development, bioprocess development, formulation development, and comprehensive analytical testing. Clients can also benefit from CMC Biologics’ proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. More detailed information can be found at www.cmcbiologics.com.
IXINITY® coagulation factor IX (recombinant) and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All rights reserved.
Logo - http://photos.prnewswire.com/prnh/20110502/SF93356LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cmc-biologics-in-commercial-supply-agreement-with-emergent-biosolutions-for-fda-approved-ixinity-300077388.html
SOURCE CMC Biologics, Inc.
Help employers find you! Check out all the jobs and post your resume.
